Posted by Michael Wonder on 11 May 2017
Institute for Clinical and Economic Review posts briefing paper on assessing the value of drugs for rare conditions
10 May 2017 - Report contains a technical brief on Spinraza and will inform discussions at ICER pricing summit on 31 May; summit participants will explore options for assessing value and establishing value-based prices for orphan drugs.
The Institute for Clinical and Economic Review (ICER) today posted a briefing paper on Assessing the Effectiveness and Value of Drugs for Rare Conditions. The briefing paper seeks to provide background information to help frame the issues to be discussed during ICER's Orphan Drug Assessment and Pricing Summit, a multi-stakeholder policy meeting to be held in Washington, DC on 31 May.
